Cryosa Inc. is focused on developing innovative, minimally invasive therapies for obstructive sleep apnea (OSA), a condition affecting millions globally. The company aims to provide a treatment that is free from masks, hoses, and implants, addressing the limitations of current therapies that many patients find intolerable. Their approach involves a proprietary technology that utilizes a controlled cooling process to reduce tissue and open airways, which is designed to be both effective and less invasive than traditional surgical options. Cryosa is currently conducting clinical studies, including a pilot study named ARCTIC-3, to evaluate the safety and effectiveness of their treatment for patients with moderate to severe OSA.

The leadership team at Cryosa comprises experienced professionals from the medical device industry, including successful entrepreneurs and engineers. Their combined expertise is directed towards creating permanent solutions for OSA, with a focus on reducing adipose tissue in the upper airway, which has been linked to the severity of the condition. The company has secured significant funding to support its research and development efforts, indicating strong investor confidence in its potential to meet the substantial unmet medical needs of OSA patients.

United States

Cryosa is a clinical stage company developing a treatment for moderate to severe Obstructive Sleep Apnea (OSA). We believe that mask-free, hose-free, implant-free treatment is possible. Everyone is free to sleep, free to rest and free to live brighter days.

Cryosa Inc.

Company Details